US92829J1043 - Common Stock - After market: 0.3215 0 (-1.08%)
NASDAQ:VIRI (1/27/2023, 7:00:02 PM)+0.01 (+3.17%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-14 2022-11-14/bmo | Earnings (Next) | N/A N/A |
Ins Owners | 4.91% | Inst Owners | 7.04% |
Market Cap | 5.96M | Shares | 18.33M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 43.33 |
IPO | 12-17 2020-12-17 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. The company is headquartered in Alpharetta, Georgia and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).
VIRIOS THERAPEUTICS INC
44 Milton Avenue
Alpharetta GEORGIA
P: 18666208655.0
Employees: 5
Website: https://www.virios.com/
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing...
It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement.
Here you can normally see the latest stock twits on VIRI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: